Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467726 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
A Phase 1 study, sponsored by Alfasigma S.p.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01467726 is a Phase 1 study that has completed, run by Alfasigma S.p.A.. The registered enrollment target is 40 participants.
The verdict
NCT01467726, a Phase 1 study, has completed, sponsored by Alfasigma S.p.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
Interventions
- DRUG Placebo
- DRUG Velusetrag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467726
The ClinicalTrials.gov registry entry for NCT01467726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alfasigma S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01467726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467726 about?
NCT01467726 is a clinical study titled "Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects". This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
What is the current status of trial NCT01467726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01467726?
The interventions under investigation include: Placebo (DRUG), Velusetrag (DRUG).
Who is sponsoring clinical trial NCT01467726?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.